MARTINSRIED/MUNICH, Germany--(BUSINESS WIRE)--4SC AG (Frankfurt, Prime Standard: VSC) a drug discovery and development company focused on autoimmune and cancer indications, today announced that Ulrich Dauer, CEO, will present an update on the company’s strategy, programmes and prospects at the 12th Annual Bio CEO and Investor Conference in New York, USA, on Monday, 8th February at 4.00pm EST/10.00pm CET.
